Asker Healthcare Group AB
71.55
SEK
+0.75
(+1.06%)
ISIN
SE0024171458
Return %
Stock
S&P 500
1Y
-15.53
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Johan Falk
- Full Time Employees
- 4,580
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- SvÄRdvÄGen 3A Danderyd AB Sweden 182 33
- IPO Date
- Mar 27, 2025
- Website
- asker.com
- Similar Companies
- Business
- Asker Healthcare Group AB (ASKER.ST) is a Sweden-based healthcare company that provides medical products, devices, equipment, and related solutions to caregivers, patients, hospitals, clinics, and healthcare institutions across Europe. Founded in 2018 and headquartered in Danderyd, Sweden, the group operates through more than 50 companies in 19 countries, employing over 4,500 people and generating revenues of SEK 16 billion; it focuses on improving patient outcomes, reducing total cost of care, and ensuring a sustainable value chain via its "twin engine" strategy of organic growth and acquisitions. Core offerings encompass a broad portfolio of medical supplies, consumables, and equipment distributed by subsidiaries such as OneMed (50,000 stocked products including devices, logistics, and services like Decision Support Guide and OneWound across Nordic and Baltic markets), Bosman (stoma, wound, diabetes, and urological care devices and support in the Netherlands), QRS (medical equipment and consumables for hospitals and clinics in Netherlands and Belgium), Diashop (diabetes care products via shops and online in Germany), FysioSupplies (physiotherapy products for professionals and consumers across Europe), and Evercare Medical (comprehensive medical supplies Europe-wide); additional services include 4PL logistics via OneMed Services, aesthetic equipment via Astomed, and specialized solutions like aScan's inventory management and EvivaMed's diabetes and wound care products. Recent developments include the acquisition of Novus Med Holdings Limited in 2025, a UK distributor of endoscopic surgery technologies and patient positioning systems that enhances minimally invasive surgery offerings and bolsters UK hospital partnerships with positive EBITA impact; the purchase of Health Net Connections, a British healthcare software firm, earlier that year; the November 2025 acquisition of InnoMedicus AG, a specialist in urology devices, software, and training for prostate cancer therapies generating SEK 50 million in 2024 revenue; acquisition of distribution rights for orthopedic implants in the Baltic region; and ongoing construction of a new distribution center in Gothenburg, supporting a robust pipeline targeting 10-20 annual acquisitions amid Q2 2025 net sales growth of 9% to SEK 4 billion and EBITDA margin progress toward 10%.